| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2017-03-01 |
复牌提示：
2017-03-01 07:49:19 停牌，复牌日期 2017-03-02 00:00:01
|
| 2016-11-28 |
详情>>
股本变动：
变动后总股本378.55万股
变动原因 ▼▲
- 原因：
- a 1-for-5 reverse stock split of its outstanding common stock will be effective at 4:01 p.m. Pacific Time on November 28, 2016
|
| 2016-11-28 |
详情>>
拆分方案：
每5.0000合并分成1.0000股
|
| 2016-11-10 |
详情>>
业绩披露：
2016年三季报(累计)每股收益-0.69美元,归母净利润-1296.5万美元,同比去年增长-7.12%
|
| 2016-10-27 |
股东大会：
将于2016-11-15召开股东大会
会议内容 ▼▲
- 1.Adoption of the Merger Agreement. To consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated as of May 12, 2016 (the “merger agreement”), by and among Takara Bio USA Holdings, Inc., a Delaware corporation (“Takara Bio”), Walrus Acquisition Corporation, a Nevada corporation and wholly owned subsidiary of Takara Bio, WaferGen Bio-systems, Inc., a Nevada corporation, and, solely for the purposes stated therein, Takara Bio USA, Inc. (“TBUSA”), a copy of which is attached as Annex A to the proxy statement accompanying this notice;
2.Potential Payments Under Compensation Arrangements. To consider and vote on a proposal to approve, on an advisory, non-binding basis, the compensation that may be paid or become payable to WaferGen’s named executive officers in connection with the merger, and the agreements and understandings pursuant to which such compensation may be paid or become payable, as described in the section of the proxy statement entitled “The Merger—Golden Parachute Arrangements for WaferGen Named Executive Officers” beginning on page 47;
3.Non-Employee Director and Strategic Committee Compensation. To consider and vote on a proposal to approve certain payments to the non-employee members of WaferGen’s board of directors and to the non-employee members of the strategic committee of WaferGen’s board of directors that was formed in November 2015 to consider and evaluate strategic opportunities and alternatives for WaferGen;
4.Adjournment. To approve any adjournments of the special meeting, if necessary, to solicit additional proxies in order to approve the foregoing proposals.
|
| 2016-08-11 |
详情>>
业绩披露：
2016年中报每股收益-0.5美元,归母净利润-929.5万美元,同比去年增长-7.74%
|
| 2016-05-12 |
详情>>
业绩披露：
2016年一季报每股收益-0.24美元,归母净利润-440.8万美元,同比去年增长8.28%
|
| 2016-04-12 |
股东大会：
将于2016-05-25召开股东大会
会议内容 ▼▲
- 1.Elect seven (7) directors to serve for a one-year term until the 2017 annual meeting of the stockholders or until their successors are duly elected and qualified;
2.Approve a grant of discretionary authority to our board of directors to amend our Amended and Restated Articles of Incorporation to effect a reverse stock split of our outstanding shares of common stock, at any time within one year after stockholder approval is obtained, by a ratio of not less than one-for-two and not more than one-for-ten, with the exact ratio to be set within this range as determined by our board of directors in its sole discretion;
3.Amend the WaferGen Bio-systems, Inc., 2008 Stock Incentive Plan to, among other things, increase the number of shares of the Company’s common stock that may be issued pursuant to awards thereunder from 1,214,589 shares to 3,714,589, extend the plan’s expiration date, and re-approve the material terms of the plan for purposes of Section 162(m) of the Internal Revenue Code of 1986;
4.Ratify the selection of SingerLewak LLP as the Company’s independent auditors to provide audit services to the Company for the fiscal year ending December 31, 2016;
5.Approve, on a non-binding advisory basis, the compensation paid to our named executive officers;
6.Transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2016-03-25 |
详情>>
业绩披露：
2015年年报每股收益-2.58美元,归母净利润-1999.3万美元,同比去年增长-86.98%
|
| 2015-11-12 |
详情>>
业绩披露：
2015年三季报(累计)每股收益-2.13美元,归母净利润-1210.3万美元,同比去年增长-62.9%
|
| 2015-08-07 |
详情>>
业绩披露：
2015年中报每股收益-1.52美元,归母净利润-862.7万美元,同比去年增长-85.57%
|
| 2015-05-14 |
详情>>
业绩披露：
2015年一季报每股收益-0.85美元,归母净利润-480.6万美元,同比去年增长-88.77%
|
| 2015-04-29 |
股东大会：
将于2015-06-10召开股东大会
会议内容 ▼▲
- 1.Elect six (6) directors to serve for a one-year term until the 2016 annual meeting of the stockholders or until their successors are duly elected and qualified;
2.Ratify the selection of SingerLewak LLP as the Company’s independent auditors to provide audit services to the Company for the fiscal year ending December 31, 2015;
3.Approve, on a non-binding advisory basis, the compensation paid to the company's named executive officers;
4.Transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2015-03-17 |
详情>>
业绩披露：
2014年年报每股收益-4.17美元,归母净利润-1069.29万美元,同比去年增长39.63%
|
| 2015-01-02 |
详情>>
内部人交易：
KANTER JOEL S等共交易3笔
|
| 2014-11-12 |
详情>>
业绩披露：
2014年三季报(累计)每股收益-4.87美元,归母净利润-742.96万美元,同比去年增长66.38%
|
| 2014-10-08 |
股东大会：
将于2014-11-17召开股东大会
会议内容 ▼▲
- 1.Amend the WaferGen Bio-systems, Inc., 2008 Stock Incentive Plan to increase the number of shares of the Company’s common stock that may be issued pursuant to awards under the plan from 314,589 shares to 1,214,589, limit the maximum number of plan shares that may be awarded to any individual in one year to 500,000, extend the plan’s expiration date, and re-approve the material terms of the plan for purposes of Section 162(m) of the Internal Revenue Code of 1986;
2.Approve the adjournment of the special meeting, if necessary, to solicit additional proxies to vote in favor of the foregoing proposal;
3.Transact such other business as may properly come before the special meeting or any adjournment or postponement thereof.
|
| 2014-08-14 |
详情>>
业绩披露：
2014年中报每股收益-5.07美元,归母净利润-464.9万美元,同比去年增长52.80%
|